Analysis of the steady-state relations and control-algorithm characterisation in a mathematical model of cholesterol biosynthesis

Elevated levels of cholesterol are known to be a risk factor for cardiovascular diseases. As a result, several treatment strategies and drugs have been developed to control these elevated cholesterol levels, but they are not always successful. Statins are now the most widely used cholesterol-lowering drugs; however, not all the mechanisms of their action are understood and this can sometimes lead to adverse effects. A dynamic mathematical model of the cholesterol biosynthesis network was developed with aim to understand the key mechanisms of cholesterol biosynthesis. In this article we show that in spite of a serious lack of experimental data, the model can be used to study the concepts of possible mechanisms of cholesterol biosynthesis and drug interactions. If only steady-state data is used for the model’s identification, the model can predict the steady-state relations after perturbation correctly, while the dynamical properties are not necessarily related to the real system. The control mechanism for the cholesterol levels through the SREBF-2 transcription factor was identified as the PI control algorithm. The comparison of model simulations and performed biological experiments indicated that the substances LK-980 and Atorvastatin most likely trigger the same indirect mechanism of cholesterol biosynthesis control, although they interact with the network in different ways.

[1]  Joachim Selbig,et al.  Metabolic networks are NP-hard to reconstruct. , 2008, Journal of theoretical biology.

[2]  Jason A. Papin,et al.  The genome-scale metabolic extreme pathway structure in Haemophilus influenzae shows significant network redundancy. , 2002, Journal of theoretical biology.

[3]  Joze Drinovec,et al.  Modeling the influence of risk factors and chronic diseases on the development of strokes and peripheral arterial-vascular disease , 2008, Simul. Model. Pract. Theory.

[4]  M. Mavrovouniotis Estimation of standard Gibbs energy changes of biotransformations. , 1991, The Journal of biological chemistry.

[5]  Peter J Espenshade,et al.  Regulation of sterol synthesis in eukaryotes. , 2007, Annual review of genetics.

[6]  Tatsuhiko Kodama,et al.  Sterol-dependent Transcriptional Regulation of Sterol Regulatory Element-binding Protein-2* , 1996, The Journal of Biological Chemistry.

[7]  G. Stephanopoulos,et al.  Computer‐aided synthesis of biochemical pathways , 1990, Biotechnology and bioengineering.

[8]  Katsuhiko Ogata,et al.  Modern Control Engineering , 1970 .

[9]  S. Baker,et al.  Clinical perspectives of statin-induced rhabdomyolysis. , 2006, The American journal of medicine.

[10]  J E Mittenthal,et al.  A new method for assembling metabolic networks, with application to the Krebs citric acid cycle. , 2001, Journal of theoretical biology.

[11]  Marc K Hellerstein,et al.  A critique of the molecular target-based drug discovery paradigm based on principles of metabolic control: advantages of pathway-based discovery. , 2008, Metabolic engineering.

[12]  Chunhui Li,et al.  Exploring the diversity of complex metabolic networks , 2005, Bioinform..

[13]  K. Monostory,et al.  Perspectives of the non-statin hypolipidemic agents. , 2010, Pharmacology & therapeutics.

[14]  Nico Van de Veire European Cardiovascular Disease Statistics 4 th edition 2012 : EuroHeart II , .

[15]  Jotun Hein,et al.  A stochastic model for the evolution of metabolic networks with neighbor dependence , 2009, Bioinform..

[16]  Naresh K. Sinha,et al.  Modern Control Systems , 1981, IEEE Transactions on Systems, Man, and Cybernetics.

[17]  Yoshihiro Yamanishi,et al.  KEGG for linking genomes to life and the environment , 2007, Nucleic Acids Res..

[18]  I. Goryanin,et al.  Human metabolic network reconstruction and its impact on drug discovery and development. , 2008, Drug discovery today.

[19]  Joze Drinovec,et al.  Simulation analysis of coronary heart disease, congestive heart failure and end-stage renal disease economic burden , 2011, Math. Comput. Simul..

[20]  Uroš Urleb,et al.  Inhibition of Human Sterol Δ7-Reductase and Other Postlanosterol Enzymes by LK-980, a Novel Inhibitor of Cholesterol Synthesis , 2011, Drug Metabolism and Disposition.

[21]  Mark Gerstein,et al.  Training set expansion: an approach to improving the reconstruction of biological networks from limited and uneven reliable interactions , 2008, Bioinform..

[22]  Linda J. Broadbelt,et al.  Computational discovery of biochemical routes to specialty chemicals , 2004 .

[23]  Maja Atanasijević-Kunc,et al.  MODELLING OF THE RISK FACTORS AND CHRONIC DISEASESTHAT INFLUENCE THE DEVELOPMENT OF SERIOUS HEALTHCOMPLICATIONS , 2008 .